Skip to main content
. 2011 Dec 23;3(3):713–717. doi: 10.3892/ol.2011.534

Figure 3.

Figure 3

Kaplan-Meier analysis of progression-free survival (PFS) of patients with or without tumor tissue EGFR sequencing data. PFS was shorter for 24 patients whose tumor tissue EGFR mutation data was unavailable compared to 30 patients who had adequate tissue samples for tumor EGFR analysis (median 5 months vs. 7.6 months, p=0.0704). EGFR, epidermal growth factor receptor.